Transcatheter Arterial Chemoembolization Therapy for Patients With Hepatocellular Carcinoma: A Case-Controlled Study  Maurizio Biselli, Pietro Andreone, Annagiulia Gramenzi, Franco Trevisani, Carmela Cursaro, Cristina Rossi, Salvatore Ricca Rosellini, Carlo Cammà, Stefania Lorenzini, Giuseppe Francesco Stefanini, Giovanni Gasbarrini, Mauro Bernardi  Clinical Gastroenterology and Hepatology  Volume 3, Issue 9, Pages 918-925 (September 2005) DOI: 10.1016/S1542-3565(05)00425-8 Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 Probability of survival in patients treated by TACE and in the control group. Clinical Gastroenterology and Hepatology 2005 3, 918-925DOI: (10.1016/S1542-3565(05)00425-8) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 2 Degree of Lipiodol uptake and survival rate. >75% vs 75%–50%, P = .0247; >75% vs <50%, P = .0032; 75%–50% vs <50%, P = not significant. Clinical Gastroenterology and Hepatology 2005 3, 918-925DOI: (10.1016/S1542-3565(05)00425-8) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 3 Probability of survival in patients treated by TACE and in the control group subdivided by CLIP score. CLIP ≤ 1 treated vs untreated, P = .038; CLIP > 1 treated vs untreated, P = .0001. Clinical Gastroenterology and Hepatology 2005 3, 918-925DOI: (10.1016/S1542-3565(05)00425-8) Copyright © 2005 American Gastroenterological Association Terms and Conditions